SAN DIEGO and PENNINGTON, N.J., Nov.
2, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced that preliminary clinical and
immunological data from its ongoing KEYNOTE-695 study, a global,
multicenter, registration-directed Phase 2b trial of TAVO™ in combination
with KEYTRUDA® for the treatment of metastatic melanoma,
were accepted for a late-breaking Poster Presentation at the
upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
to be held at the Walter E. Washington Convention Center in
Washington, D.C. on November 7-11, 2018.
The details of the Poster Presentation are as follows:
Presentation Title: Initial report of intratumoral
tavokinogene telseplasmid with pembrolizumab in advanced melanoma:
an approach designed to convert PD-1 antibody progressors into
responders.
Author: Atkinson, et. al.
Poster Number: P717
Presentation date: Friday, November
9 and Saturday, November 10,
2018
The late-breaking abstract titles can be found on the conference
website here.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Kenilworth, NJ, USA.
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on
developing cytokine-based intratumoral immunotherapies to stimulate
the body's immune system to target and attack cancer.
OncoSec's lead immunotherapy platform – TAVO™
(tavokinogene telseplasmid) – enables the intratumoral delivery of
DNA-based interleukin-12 (IL-12), a naturally occurring protein
with immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline utilizing
TAVO™ as a potential treatment for multiple cancer
indications either as a monotherapy or in combination with leading
checkpoint inhibitors; with the latter potentially enabling OncoSec
to address a great unmet medical need in oncology: anti-PD-1
non-responders. Results from recently completed clinical
studies of TAVO™ have demonstrated a local immune
response, and subsequently, a systemic effect as either a
monotherapy or combination treatment approach. In addition to
TAVO™, OncoSec is identifying and developing new
DNA-encoded therapeutic candidates and tumor indications for use
with its ImmunoPulse® platform. For more information,
please visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-preliminary-data-from-keynote-695-study-accepted-for-late-breaking-presentation-at-sitc-annual-meeting-300743017.html
SOURCE OncoSec Medical Incorporated